Physician profile
Yaniv Berger
NPI 1992962369
$12,957.26
in general payments reported to CMS, 2019-2025
52 companies · $2,009 in 2025
The $2,009 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,334 · 2020: $1,073 · 2021: $1,934 · 2022: $2,080 · 2023: $2,093 · 2024: $2,435 · 2025: $2,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,440 · Education: $96.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,440.09 |
| Education | $96.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,027.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,975.64 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,487.46 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,283.43 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $838.17 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $616.71 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $553.30 | 2019-2025 | Jardiance |
| Pfizer INC. | $524.05 | 2019-2025 | |
| Glaxosmithkline, LLC. | $446.77 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $316.99 | 2019-2025 | |
| Horizon Therapeutics Plc | $280.26 | 2021-2023 | Krystexxa |
| Amarin Pharma, INC. | $261.88 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $231.72 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $219.54 | 2019-2025 | Veozah |
| Corcept Therapeutics | $164.38 | 2023-2025 | Korlym |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaniv Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.